Intratumoral CD103(+)CD8(+) T cells predict response to neoadjuvant chemoimmunotherapy in advanced head and neck squamous cell carcinoma

BACKGROUND: Immune cell heterogenicity is known to determine the therapeutic response to cancer progression. Neoadjuvant chemoimmunotherapy (NACI) has shown clinical benefits in some patients with advanced head and neck squamous cell carcinoma (HNSCC), but the underlying mechanism behind this clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Siqi, Lan, Tianjun, Wu, Fan, Chen, Suling, Jiang, Xue, Huo, Chuying, Li, Zitian, Xie, Shule, Wu, Donghui, Wang, Ruixin, Li, Yanyan, Qiu, Lin, Huang, Guoxin, Li, Shurui, Wang, Xiaojuan, Cen, Meifeng, Cai, Tingting, Lin, Zhaoyu, Li, Jinsong, Li, Bowen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565384/
https://www.ncbi.nlm.nih.gov/pubmed/37658605
http://dx.doi.org/10.1002/cac2.12480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565384/
https://www.ncbi.nlm.nih.gov/pubmed/37658605
http://dx.doi.org/10.1002/cac2.12480

Ejemplares similares